Nitec Pharma AG None
Nitec Pharma AG is a specialty pharmaceutical company that focuses on developing and commercializing medicines to treat chronic inflammation and pain-related diseases. The company develops proprietary products based on well-characterized pharmaceuticals and disease targets to address areas of high unmet medical need within these markets. Its lead product, Lodotra, is a circadian cytokine modulator that has completed a European phase 3 trial in rheumatoid arthritis and has been recommended for European regulatory approval. Nitec is conducting a second pivotal phase 3 trial in preparation for filing an NDA with the FDA seeking US approval of Lodotra for the treatment of the signs and symptoms of RA including morning stiffness. The company's second product candidate, TruNoc, is being developed as a treatment of neuropathic pain and other chronic inflammation and pain-related diseases. Nitec is headquartered in the Basel region of Switzerland and was spun out of Merck KGaA in 2004.
